循環器臨床サピア　7　CKDと心血管病を理解する

出版社： 中山書店
著者：
発行日： 2010-03-15
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784521731674
シリーズ： 循環器臨床サピア
電子書籍版： 2010-03-15 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

近年，「心腎連関」という概念が提唱されている。特に慢性腎臓病（CKD）は強力な心血管リスクであり，CKD患者は透析に至るより心血管病を発症し死亡する確率のほうがはるかに高い。本書は循環器内科医のみならず幅広い内科医が，CKDを狭い腎疾患ととらえることなく診療にあたるべく，CKDと心血管病，さらに心腎連関を理解するために必要な知識を詳述した。

目次

  • 循環器臨床サピア　7　CKDと心血管病を理解する

    ―目次―

    1章　疫学から現状を理解する
    わが国のCKDの現状
    心血管リスクとしてのCKD
    世界と日本における腎疾患対策の方針
    CKDの医療経済

    2章　必要な検査を理解する
    GFR
    アルブミン尿・蛋白尿
    尿中L-FABP
    血中マーカー(腎臓から)
    血中メチルグリオキサール
    血中マーカー（循環器から）
    アドレノメデュリン
    心エコー（心機能評価）
    腎動脈エコー

    3章　基礎的病態を理解する
    腎血流調節
    ＮＯ
    動脈硬化
    血管石灰化
    心筋リモデリング

    4章　臨床上の課題と対策を理解する
    高血圧（CKDにおける高血圧治療の課題と対策
    腎血管性高血圧）
    糖尿病
    インスリン抵抗性
    脂質異常症
    冠動脈疾患
    造影剤腎症
    コレステロール塞栓症
    心不全
    心不全における貧血
    脳卒中
    維持透析
    貧血
    高尿酸血症

    5章　心腎保護を目指した治療戦略を理解する
    利尿薬
    利尿薬抵抗性の対策
    RA系抑制薬（循環器から／腎臓から）
    hANP（循環器から／腎臓から）
    抗不整脈薬
    スタチン／エリスロポエチン
    冠動脈インターベンション
    経皮的腎動脈形成術

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 疫学から現状を理解する

P.9 掲載の参考文献
1) Matsuo S, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009 ; 53 : 982-992.
PubMed
1) Sarnak MJ, et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 ; 108 : 2154-2169.
PubMed
2) Levey AS, et al. Chronic kidney disease as a global public health problem : Approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007 ; 72 : 247-259.
PubMed
2) National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, Classification, and Stratification. Am J Kidney Dis 2002 ; 39 (Suppl 1) : S170-S212.
 
3) 図説 : わが国の慢性透析療法の現況 (2005年12月31日現在). 日本透析医学会統計調査委員会 2006年6月22日 (東京).
 
3) Ninomiya T, Kiyohara Y. Chronic kidney diseases and other diseases : 1. Cardiovascular diseases. J J Int Med 2007 ; 96 : 887-893.
 
4) 井関邦敏. 疫学調査から見た慢性腎疾患対策の重要性. 日内会誌 2005 ; 94 : 163-168.
 
4) Vikse BE, et al. Low birth weight increases risk for end-stage renal disease. J Am Soc Nephrol 2008 ; 19 : 151-157.
 
5) Iseki K, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003 ; 63 : 1468-1474.
PubMed
6) Iseki K, et al. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004 ; 44 : 806-814.
PubMed
7) Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351 : 1296-1305.
PubMed
8) Anavekar NS, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 ; 351 : 1285-1295.
PubMed
9) 日本腎臓学会 (編). CKD診療ガイド. 2009.
 
10) Ruggenenti P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008 ; 19 : 1213-1224.
 
P.17 掲載の参考文献
1) Imai E, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009 ; 13 : 621-630.
PubMed
2) Ninomiya T, et al. Impact of kidney disease and blood pressure on the development of cardiovascular disease. An overview from the Japan Arteriosclerosis Longitudinal Study. Circulation 2008 ; 118 : 2694-2701.
PubMed
3) 二宮利治ほか. 一般住民における慢性腎臓病と心血管病発症の関係 : 久山町研究. 日本透析医学会雑誌 2006 ; 39 : 94-96.
 
4) Nakano T, et al. Association of kidney function with coronary artherosclerosis and calcification in autopsy samples from Japanese elders : The Hisayama Study. Am J Kidney Dis 2010 ; 55 : 21-30.
 
5) Perkovic V, et al. The relationship between proteinuria and coronary risk : A systematic review and meta-analysis. PLoS Med 2008 ; 5 : e207.
 
6) Ninomiya T, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009 ; 20 : 1813-1821.
PubMed
7) Shlipak MG, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005 ; 352 : 2049-2060.
 
8) 日本腎臓学会 (編). エビデンスに基づくCKD診察ガイドライン 2009. 東京 : 東京医学社 ; 2009. pp.1-16.
 
9) Garg AX, et al. Alubuminuria and renal insufficiency prevalence guides population screening : Results from the NHANES III. Kidney Int 2002 ; 61 : 2165-2175.
 
10) Konta T, et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population : The Takahata study. Kidney Int 2006 ; 70 : 751-756.
PubMed
P.23 掲載の参考文献
1) 日本腎臓学会 (編). CKD診療ガイド 2009. 東京 : 東京医学社 ; 2009.
 
2) Levey AS, et al. Definition and classification of chronic kidney disease : A position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 2005 ; 67 : 2089-2100.
PubMed
3) Levey AS, et al. Chronic kidney disease as a global public health problem : Approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007 ; 72 : 247-259.
PubMed
4) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009 ; 113 : S1-S130.
PubMed
5) Kidney Disease : Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008 ; 109 : S1-S99.
PubMed
6) Tsukamoto Y, et al. Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. "Current status and perspective of CKD in Asia" : Diversity and specificity among Asian countries. Clin Exp Nephrol 2009 ; 13 : 249-256.
PubMed
P.29 掲載の参考文献
1) Yamagata K, et al. Chronic kidney disease perspective in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008 ; 12 : 1-8.
PubMed
2) 日本透析医学会 (編). わが国の慢性透析療法の現況 (2008年12月31日現在). http://docs.jsdt.or.jp/overview/
 
3) Nakai S, et al. An overview of dialysis treatment in Japan (as of Dec. 31, 2005). J Jpn Soc Dial Ther 2007 ; 40 : 1-30.
 
4) Boulware LE, et al. Screening for proteinuria in US adults : A cost-effectiveness analysis. JAMA 2003 ; 290 : 3101-3114.
PubMed
5) Garg AX, et al. Albuminuria and renal insufficiency prevalence guides population screening : Results from the NHANES III. Kidney Int 2002 ; 61 : 2165-2175.
PubMed
6) Yamagata K, et al. Risk factors for chronic kidney disease in a community-based population : A 10-year follow-up study. Kidney Int 2007 ; 71 : 159-166.
 
7) Woolhandler S, et al. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA 1989 ; 262 : 1214-1219.
PubMed
8) Yamagata K, et al. Age distribution and yearly changes in the incidence of end-stage renal disease in Japan. Am J Kidney Dis 2004 ; 43 : 433-443.
PubMed
9) Ninomiya T, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population : The Hisayama Study. Kidney Int 2005 ; 68 : 228-236.
 
10) Hallan SI, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006 ; 17 : 2275-2284.
 
11) Hillege HL, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 ; 106 : 1777-1782.
PubMed
12) Konta T, et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population : The Takahata study. Kidney Int 2006 ; 70 : 751-756.
PubMed

2章 必要な検査を理解する

P.39 掲載の参考文献
1) 日本腎臓学会 (編). 腎機能 (GFR) ・尿蛋白測定の手引き. 東京 : 東京医学社 ; 2009.
 
2) Poggio ED, et al. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int 2009 ; 75 : 1079-1087.
PubMed
3) Agarwal R, et al. Assessment of iothalamate plasma clearance : Duration of study affects quality of GFR. Clin J Am Soc Nephrol 2009 ; 4 : 77-85.
PubMed
4) 市原文雄. 血清クレアチニンの基準範囲. 臨床化学 1995 ; 24 (suppl 2) : 229.
 
5) Levey A, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006 ; 145 : 247-254.
PubMed
6) Matsuo S, et al. Revised equations for estimating glomerular filtration rate (GFR) from serum creatinine in Japan. Am J Kidney Dis 2009 ; 53 : 982-992.
PubMed
P.46 掲載の参考文献
1) 猪股茂樹ほか. 糖尿病性腎症の新しい診断基準. 糖尿病 2005 ; 48 : 757-759.
 
1) 日本腎臓学会 (編). CKD診療ガイド 2009. 東京 : 東京医学社 ; 2009.
 
2) 羽田勝計. 特集「糖尿病 : 診断と治療の進歩 ; 合併症対策の進歩」腎症. 日本内科学会雑誌 2009 ; 98 (4) : 61-66.
 
P.48 掲載の参考文献
1) Kamijo-Ikemori A, et al. Urinary fatty acid binding protein in renal disease. Clin Chim Acta 2006 ; 374 : 1-7.
PubMed
2) Nakamura T, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007 ; 333 : 321-326.
PubMed
3) Nakamura T, et al. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy. Metabolism 2009 ; 58 : 1185-1190.
PubMed
4) Portilla D, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008 ; 73 : 465-472.
PubMed
P.50 掲載の参考文献
1) Matsuo S, et al. Revised equations for estimating glomerular filtration rate (GFR) from serum creatinine in Japan. Am J Kidney Dis 2009 ; 53 : 982-992.
PubMed
2) 市原文雄. 血清クレアチニンの基準範囲. 臨床化学 1995 ; 24 (Suppl) : 229.
 
3) Imai E, et al. Slower decline of glomerular filtration rate in the Japanese general population : A longitudinal 10-year follow-up study. Hypertens Res 2008 ; 31 : 433-441.
PubMed
4) Chalasani N, et al. Blood urea nitrogen to creatinine concentration in gastrointestinal bleeding : A reappraisal. Am J Gastroenterol 1997 ; 92 : 1796-1799.
PubMed
5) Newman DJ, Cystatin C. Ann Clin Biochem 2002 ; 39 : 89-104.
PubMed
6) Newman DJ, et al. Serum cystatin C measured by automated immunoassay : A more sensitivity marker of changes in GFR than serum creatinine. Kidney Int 1995 ; 47 : 312-318.
PubMed
P.53 掲載の参考文献
1) Nakayama M, et al. Radical generation by the non-enzymatic reaction of methylglyoxal and hydrogen peroxide. Redox Rep 2007 ; 12 : 125-133.
PubMed
1) Baba SP, et al. Reductive metabolism of AGE precursors : A metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes 2009 ; 58 : 2486-2497.
PubMed
2) Gawlowski T, et al. Heat shock protein 27 modification is increased in the human diabetic failing heart. Horm Metab Res 2009 ; 41 : 594-599.
PubMed
2) Ali MA, et al. The lactate-dependent enhancement of hydroxyl radical generation by the Fenton reaction. Free Radic Res 2000 ; 32 : 429-438.
PubMed
3) Ramasamy R, et al. Methylglyoxal comes of AGE. Cell 2006 ; 124 : 258-260.
PubMed
4) Nakayama K, et al. Plasma alpha-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. Am J Nephrol 2008 ; 28 : 871-878.
PubMed
P.61 掲載の参考文献
1) Tsutamoto T, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006 ; 47 : 582-586.
PubMed
2) Tsutamoto T, et al. Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. Eur J Heart Fail 2007 ; 9 : 667-673.
 
3) Maeda K, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998 ; 135 : 825-832.
PubMed
4) Maisel AS, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002 ; 347 : 161-167.
PubMed
5) McCullough PA, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure : An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003 ; 41 : 571-579.
PubMed
6) Maeda K, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998 ; 135 : 825-832.
PubMed
7) Tsutamoto T, et al. Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J 2007 ; 71 : 1873-1878.
 
8) Tsutamoto T, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure : Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997 ; 96 : 509-516.
PubMed
P.63 掲載の参考文献
1) 加藤丈司ほか. アドレノメデュリンの基礎と新たな可能性. 循環器科 2008 ; 64 : 448-455.
 
2) 北村和雄. アドレノメデュリン. 日本臨牀増刊号 (分子腎臓病学 : 分子生物学的アプローチと分子病態生理学) 2006 ; 64 : 217-221.
 
3) 北村和雄, 江藤胤尚. アドレノメデュリン. 日本臨牀増刊号 (広範囲血液・尿化学検査, 免疫学的検査 : その数値をどう読むか) 2005 ; 63 : 592-594.
 
P.72 掲載の参考文献
1) Scharer K, et al. Cardiac function and structure in patients with chronic renal failure. Pediatr Nephrol 1999 ; 13 : 951-965.
PubMed
2) Oh JK, et al. Assessment of diastolic function and diastolic heart failure. In : Oh JK, et al (editors). The Echo Manual, 3rd edition. Philadelphia : Lippincott Williams & Wilkins ; 2006. pp.120-142.
 
3) Appleton CP. Evaluation of diastolic function by two-dimensional and Doppler assessment of left ventricular filling including pulmonary venous flow. In : Klein AL, Garcia MJ (editors). Diastology : Clinical Approach to Diastolic Heart Failure. Philadelphia : Saunders ; 2008. pp.115-143.
 
4) Ommen SR, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures : A comparative simultaneous Dopplercatheterization study. Circulation 2000 ; 102 : 1788-1794.
PubMed
5) Garcia MJ, et al. An index of early left ventricular filling that combined with pulsed Doppler peak E velocity may estimate capillary wedge pressure. J Am Coll Cardiol 1997 ; 29 : 448-454.
 
P.78 掲載の参考文献
1) Strandness DE Jr. Duplex imaging for the detection of renal artery stenosis. Am J Kidney Dis 1994 ; 24 : 674-678.
PubMed
2) Ripolles T, et al. Utility of intrarenal Doppler ultrasound in the diagnosis of renal artery stenosis. Eur J Radiol 2001 ; 40 : 54-63.
PubMed
3) Platt JF, et al. Intrarenal arterial Doppler sonography in patients with nonobstructive renal disease : Correlation of resistive index with biopsy findings. AJR Am J Roentgenol 1990 ; 154 : 1223-1227.
PubMed
4) Ohta Y, et al. Increased renal resistive index in atherosclerosis and diabetic nephropathy assessed by Doppler sonography. J Hypertens 2005 ; 23 : 1905-1911.
PubMed
5) Radermacher J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001 ; 344 : 410-417.
PubMed
6) Radermacher J, et al. Renal resistance index and progression of renal disease. Hypertension 2002 ; 39 (Pt 2) : 699-703.
 

3章 基礎的病態を理解する

P.86 掲載の参考文献
1) Ito S, et al. Strain vessel hypothesis : A viewpoint for linkage of albuminuria and cerebrocardiovascular risk. Hypertens Res 2009 ; 32 : 115-121.
PubMed
2) Ito S, Abe K. Contractile properties of afferent and efferent arterioles. Clin Exp Pharmacol Physiol 1997 ; 24 : 532-535.
PubMed
3) Mori T, Cowley AW Jr. Role of pressure in angiotensin II-induced renal injury : Chronic servo-control of renal perfusion pressure in rats. Hypertension 2004 ; 43 : 752-759.
PubMed
4) Cowley AW Jr. Long-term control of arterial blood pressure. Physiol Rev 1992 ; 72 : 231-300.
PubMed
5) Ito S, et al. Heterogeneity of angiotensin action in renal circulation. Kidney Int 1997 ; 63 : S128-S131.
PubMed
6) Mori T, et al. High perfusion pressure accelerates renal injury in salt-sensitive hypertension. J Am Soc Nephrol 2008 ; 19 : 1472-1482.
 
7) Hillege HL, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 ; 106 : 1777-1782.
 
8) Cowley AW Jr, et al. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol 2003 ; 284 : R1355-R1369.
 
9) Mori T, et al. Enhanced superoxide production in renal outer medulla of Dahl salt-sensitive rats reduces nitric oxide tubular-vascular cross-talk. Hypertension 2007 ; 49 : 1336-1341.
PubMed
10) Mori T, Cowley AW Jr. Renal oxidative stress in medullary thick ascending limbs produced by elevated NaCl and glucose. Hypertension 2004 ; 43 : 341-346.
 
P.98 掲載の参考文献
1) 柏原直樹. 糖尿病 : 糖尿病患者の腎臓を守ろう. 慢性腎臓病CKD-病態理解に基づいた予防と治療のあり方. 伊藤貞嘉, 柏原直樹 (監). 東京 : メディカルレビュー社 ; 2009. pp.25-39.
 
1) Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006 ; 70 : 1214-1222.
PubMed
2) Satoh M, et al. NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005 ; 288 : F1144-F1152.
PubMed
3) Deen WM. What determines glomerular capillary permeability? J Clin Invest 2004 ; 114 : 1412-1414.
PubMed
P.104 掲載の参考文献
1) Chade AR, et al. Kidney in early atherosclerosis. Hypertension 2005 ; 45 : 1042-1049.
PubMed
2) Schiffrin EL, et al. Chronic kidney disease : Effects on the cardiovascular system. Circulation 2007 ; 116 : 85-97.
PubMed
3) Hage FG, et al. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009 ; 53 : 2129-2140.
PubMed
4) 石橋敏幸. 終末糖化産物. 医学のあゆみ 2007 ; 221 : 1184-1189.
Medical*Online
5) 平田陽一郎, 佐田政隆. 血管リモデリングと血管周囲脂肪組織. アディポサイエンス 2009 ; 6 (2) : 155-159.
Medical*Online
P.114 掲載の参考文献
1) Wilson PW, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001 ; 103 : 1529-1534.
PubMed
2) Hashimoto H, et al. Validity and usefulness of aortic arch calcification in chest X-ray. J Atheroscler Thromb 2009 ; 16 : 256-264.
PubMed
3) Ehara S, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction : An intravascular ultrasound study. Circulation 2004 ; 110 : 3424-3429.
PubMed
4) Kondos GT, et al. Electron-beam tomography coronary artery calcium and cardiac events : A 37-month follow-up of 5635 initially asymptomatic low-to intermediate-risk adults. Circulation 2003 ; 107 : 2571-2576.
PubMed
5) Ohya Y, et al. Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort. Am J Kidney Dis 2006 ; 47 : 790-797.
 
6) Tonelli M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005 ; 112 : 2627-2633.
PubMed
7) Son BK, et al. Statins protect human aortic smooth muscle cells from inorganic phosphateinduced calcification by restoring Gas6-Axl survival pathway. Circ Res 2006 ; 98 : 1024-1031.
PubMed
8) Son BK, et al. Mechanism of pi-induced vascular calcification. J Atheroscler Thromb 2008 ; 15 : 63-68.
PubMed
P.119 掲載の参考文献
1) Katz AM, Lorell BH. Regulation of cardiac contraction and relaxation. Circulation 2000 ; 102 (Suppl 4) : IV69-IV74.
 
2) Braunwald E, Bristow MR. Congestive heart failure : Fifty years of progress. Circulation 2000 ; 102 (Suppl 4) : IV14-IV23.
 
3) 日本高血圧学会. 高血圧治療ガイドライン 2009 (JSH 2009).
 

4章 臨床上の課題と対策を理解する

P.131 掲載の参考文献
1) 日本腎臓学会・日本高血圧学会 (編). CKD (慢性腎臓病) 診療ガイド-高血圧編. 日本腎臓学会・日本高血圧学会合同学術企画. 東京 : 東京医学社 ; 2008.
 
2) Saruta T, et al. Effect of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease : Subanalysis of the CASE-J Study. Hypertens Res 2009 ; 32 : 505-512.
 
3) Bakris GL, et al. Effects of different ACE inhibitor combinations on albuminuria : Results of the GUARD study. Kidney Int 2008 ; 73 : 1303-1309.
PubMed
4) Jamerson K, et al. Benazepril plus amlodipine or hydrochloride for hypertension in highrisk patients. N Engl J Med 2008 ; 359 : 2417-2428.
 
5) Mann JE, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet 2008 ; 372 : 547-553.
PubMed
P.139 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン 2009年版 (JSH 2009). 東京 : ライフサイエンス出版 ; 2009.
 
1) Bax L, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function : A randomized trial. Ann Intern Med 2009 ; 150 : 840-848.
PubMed
2) Wheatley K, et al, ASTRAL Collaborative Group. Lack of benefit of renal artery revascularization in atherosclerotic renovascular disease (ARVD) : Results of the ASTRAL Trial. Presented at Renal Week 2008, 41st Annual Meeting & Scientific Exposition, Philadelphia, 4-9 November 2008. Abstract F-FC206.
 
2) Stephen C. Textor, renovascular hypertension and ischemic nephropathy. In : Brenner BM, et al (editors). Brenner & Rector's The Kidney, 7th edition. Philadelphia : W. B. Saunders ; 2003. pp.2065-2108.
 
3) 長谷部直幸, 菊池健次郎. 循環器学2005年の進歩 高血圧研究の進歩. 循環器専門医 2006 ; 14 (1) : 98-102.
 
4) Hasebe N, Kikuchi K, NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension : the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005 ; 23 : 445-453.
 
5) Fujino T, et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest 2004 ; 114 : 805-812.
 
P.146 掲載の参考文献
1) 日本糖尿病対策推進会議 (日本医師会・日本糖尿病学会・日本糖尿病協会) 「糖尿病治療のエッセンス作成委員会」 (編). 糖尿病治療のエッセンス. 2007年版. http://www.med.or.jp/chiki/diabetesp.pdf.
 
2) 日本糖尿病学会 (編). 糖尿病治療ガイド 2008-2009. 東京 : 文光堂 ; 2008.
 
3) 日本糖尿病学会 (編). 糖尿病食事療法のための食品交換表, 第6版. 東京 : 文光堂 ; 2008.
 
P.151 掲載の参考文献
1) Kawanami D, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells : A new insight into adipocytokine-endothelial cell interaction. Biochem Biophys Res Commun 2004 ; 314 : 415-419.
PubMed
2) Kurella M, et al. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005 ; 16 : 2134-2140.
PubMed
3) Utsunomiya K, et al. Association of urinary albumin excretion with insulin resistance in Japanese subjects : Impact of gender difference on insulin resistance. Intern Med 2009 ; 48 : 1621-1627.
PubMed
4) Brantsma AH, et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005 ; 28 : 2525-2530.
 
P.156 掲載の参考文献
1) Shoji T, et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int 2002 ; 61 : 2187-2192.
PubMed
2) Shinohara K, et al. Arterial stiffness in predialysis patients with uremia. Kidney Int 2004 ; 65 : 936-943.
PubMed
3) Kimoto E, et al. Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J Am Soc Nephrol 2006 ; 17 : 2245-2252.
PubMed
4) Shoji T, et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997 ; 131 : 229-236.
PubMed
5) Ikewaki K, et al. Delayed in vivo catabolism of intermediate-density lipoprotein and lowdensity lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 2005 ; 25 : 2615-2622.
PubMed
6) Shoji T, et al. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992 ; 41 : 1653-1661.
PubMed
7) Miida T, et al. LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol 2003 ; 14 : 732-738.
PubMed
8) Shoji T, et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998 ; 9 : 1277-1284.
PubMed
9) Shoji T, et al. Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 2000 ; 153 : 257-258.
PubMed
10) Wanner C, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005 ; 353 : 238-248.
PubMed
11) Fellstrom BC, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009 ; 360 : 1395-1407.
PubMed
12) Tonelli M, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004 ; 110 : 1557-1563.
PubMed
13) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals : A randomised placebo-controlled trial. Lancet 2002 ; 360 : 7-22.
PubMed
14) Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003 ; S207-S210.
PubMed
15) Nakamura H, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009 ; 206 : 512-517.
PubMed
16) Colhoun HM, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes : An analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009 ; 54 : 810-819.
PubMed
17) K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003 ; 41 : I-IV, S1-S91.
 
18) Sandhu S, et al. Statins for improving renal outcomes : A meta-analysis. J Am Soc Nephrol 2006 ; 17 : 2006-2016.
PubMed
P.164 掲載の参考文献
1) McCullough PA. Chronic kidney disease : Tipping the scale to the benefit of angiotensinconverting enzyme inhibition in patients with coronary artery disease. Circulation 2006 ; 114 : 6-7.
 
2) Go AS, et al. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351 : 1296-1305.
PubMed
3) Libby P, Aikawa M. Stabilization of atherosclerotic plaques : New mechanisms and clinical targets. Nat Med 2002 ; 8 : 1257-1262.
PubMed
4) Vasan RS. Biomarkers of cardiovascular disease : Molecular basis and practical considerations. Circulation 2006 ; 113 : 2335-2362.
PubMed
5) Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : Prospective observational study. BMJ 2000 ; 321 : 405-412.
PubMed
6) Goicoechea M, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006 ; 17 : s231-s235.
PubMed
7) Sarnak MJ, et al. Kidney disease as a risk factor for development of cardiovascular disease : A statement from American Heart Association Councils on Kidney in Cardiovascular Disease. High Blood Pressure Research, Clinical cardiology, and Epidemiology and Prevention. Circulation 2003 ; 108 : 2154-2169.
PubMed
P.167 掲載の参考文献
1) Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 2003 ; 181 : 1463-1471.
PubMed
2) Levy EM, et al. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996 ; 275 : 1489-1494.
PubMed
3) Gruberg L, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000 ; 36 : 1542-1548.
PubMed
4) Lindsay J, et al. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB versus rise of serum creatinine. Am J Cardiol 2004 ; 94 : 786-789.
PubMed
5) McCullough PA, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006 ; 98 (6A) : 27K-36K.
PubMed
6) McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008 ; 51 : 1419-1428.
PubMed
7) Mehran R, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention : Development and initial validation. J Am Coll Cardiol 2004 ; 44 : 1393-1399.
PubMed
8) McCullough PA, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006 ; 98 (6A) : 5K-13K.
PubMed
9) Marenzi G. Prophylactic hemodialysis for the prevention of contrast-induced nephropathy after coronary angiography. Nat Clin Pract Nephrol 2008 ; 4 : 130-131.
PubMed
10) Marenzi G, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006 ; 354 : 2773-2782.
PubMed
P.170 掲載の参考文献
1) Scolari F, et al. Cholesterol crystal embolism : A recognizable cause of renal disease. Am J Kidney Dis 2000 ; 36 :1089-1109.
PubMed
2) Meyrier A. Cholesterol crystal embolism : Diagnosis and treatment. Kidney Int 2006 ; 69 : 1308-1312.
PubMed
P.178 掲載の参考文献
1) Adams KF Jr, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States : Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005 ; 149 : 209-216.
 
2) Hamaguchi S, et al. Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan-report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009 ; 73 : 1442-1447.
PubMed
3) Heywood JT. The cardiorenal syndrome : Lessons from the ADHERE database and treatment options. Heart Fail Rev 2004 ; 9 : 195-201.
PubMed
4) Hillege HL, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000 ; 102 : 203-210.
PubMed
5) Fonarow GC, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure : Classification and regression tree analysis. JAMA 2005 ; 293 : 578-580.
 
6) Stork S, et al. Prediction of mortality risk in the elderly. Am J Med 2006 ; 119 : 519-525.
PubMed
7) Firth JD, et al. Raised venous pressure : A direct cause of renal sodium retention in oedema? Lancet 1988 ; 1 : 1033-1035.
PubMed
8) Bongartz LG, et al. The severe cardiorenal syndrome : 'Guyton revisited'. Eur Heart J 2005 ; 26 : 11-17.
PubMed
9) Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001 ; 96 : 132-143.
PubMed
10) Landry DW, et al. The pathogenesis of vasodilatory shock. N Engl J Med 2001 ; 345 : 588-595.
 
P.181 掲載の参考文献
1) Adlbrecht C, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008 ; 29 : 2343-2350.
 
2) Nanas JN, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006 ; 48 : 2485-2489.
PubMed
3) Naito Y, et al. Adaptive response of the heart to long term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009 ; 296 : H585-H593.
 
4) Ghali JK, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008 ; 117 : 526-535.
PubMed
5) Drueke TB, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006 ; 355 : 2071-2084.
PubMed
6) Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 ; 355 : 2085-2098.
PubMed
P.188 掲載の参考文献
1) Ninomiya T, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population : The Hisayama Study. Kidney Int 2005 ; 68 : 228-236.
 
2) Koren-Morag R, et al. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 2006 ; 67 : 224-228.
PubMed
3) Irie F, et al. The relationship of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006 ; 69 : 1264-1271.
PubMed
4) Nakayama M, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant 2007 ; 22 : 1910-1915.
 
5) 内山真一郎ほか. 脳疾患と腎機能. シンポジウム : 心血管イベント危険因子としての慢性腎臓病 (CKD). 日内会誌 2008 ; 97 : 2137-2141.
 
6) 丸山健二ほか. 第48回日本神経学会総会発表. 名古屋. 2007.
 
7) Toyoda K, et al. Stroke in patients on maintenance hemodialysis : A 22-year single-center study. Am J Kidney Dis 2005 ; 45 : 1058-1066.
PubMed
8) Ninomiya T, et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease : PROGRESS trial. Kidney Int 2008 ; 73 : 963-970.
PubMed
9) Nakamura H, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009 ; 206 : 512-517.
PubMed
10) Abramson JL, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population : The ARIC Study. Kidney Int 2003 ; 64 : 610-615.
 
11) 脳卒中合同ガイドライン委員会. 脳卒中治療ガイドライン 2009. 日本脳卒中学会ほか (編). 2009.
 
12) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients: Guideline 9 cerebrovascular disease. Am J Kidney Dis 2005 ; 45 (Suppl 3) : 18-21.
 
13) Notaro LA, et al. Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease : focus on pharmacological therapy. Cardiovasc Ther 2009 ; 27 : 199-215.
PubMed
P.194 掲載の参考文献
1) Sarnak MJ, et al. Kidney disease as a risk factor for development of cardiovascular disease : A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 ; 108 : 2154-2169.
PubMed
2) Anavekar NS, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 ; 351 : 1285-1295.
PubMed
3) 日本透析医学会 (編). わが国の慢性透析療法の現況 (2008年12月31日現在). http://docs.jsdt.or.jp/overview/
 
4) Hase H, et al. Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int 2006 ; 70 : 1142-1148.
 
5) McIntyre CW, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 2008 ; 3 : 19-26.
 
6) Levin A, et al. Left ventricular mass index increase in early renal disease : Impact of decline in hemoglobin. Am J Kidney Dis 1999 ; 34 : 125-134.
PubMed
7) Silberberg JS, et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989 ; 36 : 286-290.
PubMed
8) Ayus JC, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers : A prospective, controlled study. J Am Soc Nephrol 2005 ; 16 : 2778-2788.
PubMed
9) Strozecki P, et al. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001 ; 23 : 115-126.
PubMed
10) Galetta F, et al. Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med 2005 ; 258 : 378-384.
PubMed
11) Neves KR, et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004 ; 66 : 2237-2244.
PubMed
12) Dhingra R, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007 ; 167 : 879-885.
 
13) Foley RN, et al. Serum phosphate and left ventricular hypertrophy in young adults : The coronary artery risk development in young adults study. Kidney Blood Press Res 2009 ; 32 : 37-44.
PubMed
P.199 掲載の参考文献
1) Kannel W. Epidemiology and prevention of cardiac failure : Framingham Study insights. Eur Heart J 1987 ; 8 (Suppl F) : 23-26.
 
2) Jurkovitz CT, et al. Association of High Serum Creatinine and Anemia Increases the Risk of Coronary Events : Results from the Prospective Community-Based Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 2003 ; 14 : 2919-2925.
PubMed
3) Mohanram A, et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004 ; 66 : 1131-1138.
PubMed
4) Silverberg D, et al. The cardio-renal anaemia syndrome : Does it exist? Nephrol Dial Transplant 2003 ; 18 (Suppl 8) : viii7-12.
 
5) Iseki K, Kohagura K. Anemia as a risk factor for chronic kidney disease. Kidney Int 2007 ; 72 : S4-S9.
 
6) Moranne O, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009 ; 20 : 164-171.
PubMed
7) 椿原美治ほか. 2008年版日本透析医学会「慢性腎臓病患者における腎性貧血治療のガイドライン」．日本透析医学会雑誌 2008 ; 41 : 661-716.
 
8) Phrommintikul A, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin : A meta-analysis. Lancet 2007 : 369 : 381-388.
PubMed
9) Fishbane S, Berns FS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005 ; 68 : 1337-1343.
 
P.204 掲載の参考文献
1) Fang J, Alderman MH. Serum uric acid cardiovascular mortality : The NHANES I epidemiologic follow-up study. JAMA 2000 ; 283 : 2404-2410.
PubMed
2) 富田真佐子ほか. 血清尿酸値の変動が生命予後に及ぼす影響-固定集団の長期追跡調査. プリン・ピリミジン代謝 1998 ; 22 : 133-139.
 
3) 箱田雅之ほか. 心血管疾患リスクファクターとしての尿酸値の意義 : 原爆被爆者の長期追跡調査による解析. 痛風と核酸代謝 2000 ; 24 : 61.
 
4) Alderman MH, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999 ; 34 : 144-150.
PubMed
5) Verdecchia P, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension : The PIUMA study. Hypertension 2000 ; 36 : 1072-1078.
PubMed
6) Hoieggen A, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004 ; 65 : 1041-1049.
PubMed
7) Anker SD, et al. Uric acid and survival in chronic heart failure : Validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003 ; 107 : 1991-1997.
PubMed
8) Leyva F, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997 ; 18 : 858-865.
PubMed
9) Enomoto A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002 ; 417 : 447-452.
PubMed
10) 藤森新. 高尿酸血症の薬物治療. 医薬の門 2007 ; 47 : 44-50.
 

5章 心腎保護を目指した治療戦略を理解する

P.213 掲載の参考文献
1) Chobanian AV, et al. JNC 7 : Complete report. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 ; 42 : 1206-1252.
 
2) Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999 ; 341 : 709-717.
PubMed
3) Psaty BM, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003 ; 289 : 2534-2544.
PubMed
4) 木村玄次郎. 高血圧治療と利尿薬. 呼吸と循環 2006 ; 54 : 71-80.
 
5) Krammer BK, et al. Diuretic therapy and diuretic resistance in cardiac failure. Nephrol Dial Transplant 1999 ; 14 (Suppl.4) : 39-42.
 
P.215 掲載の参考文献
1) Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001 ; 96 : 132-143.
PubMed
P.223 掲載の参考文献
1) 工藤陽子, 小室一成. レニン・アンジオテンシン系阻害薬の使い方. 松崎益徳, 伊藤貞嘉 (編). 心腎連関を識る-心から腎を, 腎から心を診る. 東京 : 文光堂 ; 2008. pp.114-117.
 
2) Saltzman HE, et al. Renal dysfunction in heart failure patients : What is the evidence? Heart Fail Rev 2007 ; 12 : 37-47.
PubMed
3) Wetmore JB, Shireman TI. The ABCs of cardioprotection in dialysis patients: A systematic review. Am J Kidney Dis 2009 ; 53 : 457-466.
PubMed
4) Bakris CL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevation in serum creatinine. Arch Intern Med 2000 ; 160 : 685-693.
 
5) Berger AK, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kediney disease. Am Heart J 2007 ; 153 : 1064-1073.
PubMed
P.231 掲載の参考文献
1) Parving HH, et al. The effect of irbesartin on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 ; 345 : 870-878.
 
2) Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 ; 345 : 861-869.
PubMed
3) de Zeeuw D, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy : Lessons from RENAAL. Kidney Int 2004 ; 65 : 2309-2320.
PubMed
4) de Zeeuw D, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004 ; 110 : 921-927.
PubMed
5) Bakris GL, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000 ; 36 : 646-661.
 
6) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編). 高血圧治療ガイドライン 2009. 日本高血圧学会, 2009.
 
7) 日本腎臓学会 (編). CKD診療ガイド 2009. 東京 : 東京医学社 ; 2009.
 
8) 日本腎臓学会 (編). エビデンスに基づくCKD診療ガイドライン 2009. 東京 : 東京医学社 ; 2009.
 
9) Ruggenenti P, Remuzzi G. Proteinuria : Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009 ; 5 : 436-437.
PubMed
10) Jamerson K, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertention in high-risk patients. N Engl J Med 2008 ; 359 : 2417-2428.
 
11) Bakris GL, et al. Effects of different ACE inhibitor combinations of albuminuria : Results of the GUARD study. Kidney Int 2008 ; 73 : 1303-1309.
PubMed
12) 日本腎臓学会・日本高血圧学会 (編). CKD診療ガイド-高血圧編. 東京 : 東京医学社 ; 2008.
 
13) Barnett AH, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004 ; 351 : 1952-1961.
PubMed
14) Kunz R, et al. Meta-analysis : Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal desease. Ann Intern Med 2008 ; 148 : 30-48.
 
15) Mann JF, et al. Renal outcomes with telmisartan, remipril, or both, in people at high vascular risk (the ONTARGET study) : A multecentre, randomized, double-blind, controlled trial. Lancet 2008 ; 372 : 547-553.
PubMed
P.237 掲載の参考文献
1) Kasama S, et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008 ; 29 : 1485-1494.
PubMed
1) 小武海公明, 吉村道博. 利尿薬の有用性. Mebio 2008 ; 25 (7) : 38-45.
Medical*Online
2) Levin ER, et al. Natriuretic peptides. N Engl J Med 1998 ; 339 : 321-328.
PubMed
2) 吉村道博. 心不全の重症度とANP, BNP. Heart View 2006 ; 10 : 430-437.
Medical*Online
3) Komukai K, et al. Decrease renal function as an independent predictor of re-hospitalization for congestive heart failure. Circ J 2008 ; 72 : 1152-1157.
PubMed
4) Saito Y, et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure : Beneficial effects on left ventricular function. Circulation 1987 ; 76 : 115-124.
PubMed
5) Lopez MJ, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995 ; 378 : 65-68.
PubMed
6) Kitakaze M, et al, J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND) : Two randomised trials. Lancet 2007 ; 370 : 1483-1493.
PubMed
7) Hayashi M, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001 ; 37 : 1820-1826.
PubMed
P.241 掲載の参考文献
1) 笠原正登ほか. 急性腎障害 (AKI) の保存的診療-造影剤腎症. Intensivist 2009 ; 1 : 543-550.
 
2) Kasahara M, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 2000 ; 11 : 1691-1701.
PubMed
3) Suganami T, et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol 2001 ; 12 : 2652-2663.
PubMed
4) Saito Y, et al. Clinical application of natriuretic polypeptide in patients with congestive heart failure : Beneficial effects on left ventricular function. Circulation 1987 ; 76 : 115-124.
PubMed
P.249 掲載の参考文献
1) Bongartz LG, et al. The severe cardiorenal syndrome : 'Guyton revisited'. Eur Heart J 2005 ; 26 : 11-17.
PubMed
2) Morikawa M, et al. Effects of moderate hyperkalemia on sinus node. Evaluation in anesthetized dogs. ASAIO Trans 1990 ; 36 : 40-42.
PubMed
3) Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351 : 1296-1305.
PubMed
4) Sarnak MJ, et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003 ; 108 : 2154-2169.
PubMed
5) Patfrey PS, et al. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 1990 ; 55 : 114-120.
 
6) 相澤義房, 筒井牧子. 透析患者の不整脈の診断. 透析患者の循環器合併症-その管理と治療のこつ. 東京 : 中外医学社 ; 1997.
 
P.255 掲載の参考文献
1) 日本腎臓病学会 (編). CKD診療ガイド 2009. 東京 : 東京医学社 ; 2009.
 
2) 日本動脈硬化学会 (編). 脂質異常症治療ガイド 2008年度版. 東京 : 協和企画 ; 2008.
 
3) Benson D, et al. Chronic kidney disease and statins : Improving cardiovascular outcomes. Curr Atherosclerosis Rep 2009 ; 11 : 301-308.
 
4) Ritz E, Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 2008 ; 19 : 1065-1070.
 
5) 前田真貴子ほか. 治療薬の代謝と薬物相互作用. 山下静也 (編). 脂質異常症. 大阪 : 最新医学社 ; 2008. pp.335-343.
 
6) 日本動脈硬化学会 (編). 動脈硬化性疾患予防ガイドライン 2007年度版. 東京 : 協和企画 ; 2008.
 
P.260 掲載の参考文献
1) Astor BC, et al. Association of kidney function with anemia. Arch Intern Med 2002 ; 162 : 1401-1408.
PubMed
2) Silverberg DS, et al. The interaction between heart failure, renal failure and anemia-the cardio-renal syndrome. Blood Purif 2004 ; 22 : 277-284.
PubMed
3) 椿原美治ほか. 図解CRA症候群. 大阪 : 医薬ジャーナル社 ; 2008.
 
4) Silverberg DS, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron : A randomized controlled study. J Am Coll Cardiol 2001 ; 37 : 1775-1780.
 
5) Kuriyama S, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997 ; 77 : 176-185.
PubMed
6) Gouva C, et al. Treating anemia early in renal failure patients slows the decline of renal function : A randomized controlled trial. Kidney Int 2004 ; 66 : 753-760.
PubMed
7) Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 ; 355 : 2085-2098.
PubMed
8) Nemoto T, et al. Recombinant erythropoietin rapidly treats anemia in ischemic acute failure. Kidney Int 2001 ; 59 : 246-251.
PubMed
9) Bahlmann FH, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004 ; 110 : 1006-1012.
 
10) Johnson DW, et al. Novel renoprotective actions of erythropoietin : New uses for an old hormone. Nephrology 2006 ; 11 : 306-312.
PubMed
P.262 掲載の参考文献
1) Tang YD, Katz SD. Anemia in chronic heart failure : Prevalence, etiology, clinical correlates, and treatment options. Circulation 2006 ; 113 : 2454-2461.
PubMed
2) Asaumi Y, et al. Protective role of endogenous erythropoietin system in non-hematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007 ; 115 : 2022-2032.
 
3) Namiuchi S, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005 ; 45 : 1406-1412.
PubMed
P.268 掲載の参考文献
1) Herzog CA. How to manage the renal patient with coronary heart disease : The agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003 ; 14 : 2556-2572.
PubMed
2) Hemmelgarn BR, et al. Survival after coronary revascularization among patients with kidney disease. Circulation 2004 ; 110 : 1890-1895.
PubMed
3) Keeley EC, et al. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol 2003 ; 92 : 509-514.
PubMed
4) Aoki J, et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease : Insights from ARTS trial. Eur Heart J 2005 ; 26 : 1488-1493.
PubMed
5) Nevis IF, et al. Optimal method of coronary revascularization in patients receiving dialysis : Systematic review. Clin J Am Soc Nephrol 2009 ; 4 : 369-378.
PubMed
6) Charytan D, et al. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J 2006 ; 152 : 558-564.
PubMed
7) Bonello L, et al. Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. Am J Cardiol 2008 ; 102 : 535-540.
PubMed
8) Szczech LA, et al. Outcomes of patients with chronic renal insufficiency in the Bypass Angioplasty Revascularization Investigation. Circulation 2002 ; 105 : 2253-2258.
PubMed
9) Ota T, et al. Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. Am Heart J 2009 ; 158 : 92-98.
PubMed
10) Nikolsky E, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004 ; 94 : 300-305.
PubMed
P.273 掲載の参考文献
1) Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001 ; 344 : 431-442.
PubMed
2) Yamashita T, et al. Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. Hypertens Res 2002 ; 25 : 553-557.
PubMed
3) Hirsch AT, et al. AHA/ACC 2005 Guidelines for the management of patients with peripheral arterial disease (Lower extremity, renal, mesenteric, and abdominal aortic). J Am Coll Cardiol 2006 ; 47 : 1239-1312.
PubMed
4) Conlon PJ, et al. Survival in renal vascular disease. J Am Soc Nephrol 1998 ; 9 : 252-256.
PubMed
5) ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009 ; 361 : 1953-1962.
PubMed

書評

最近チェックした商品履歴

Loading...